Now I have all the information needed. Let me write the consolidated review.

## Summary
2-3 sentence summary of the paper's contribution.

## Strengths
- strength 1 with evidence
- strength 2 with evidence

## Weaknesses
### Fatal
### Major
### Minor
### Trivial

## Nice-to-Haves

## Removed Points

## Novel Insights

## Suggestions

## Score and Decision

Let me draft this now.

---

**Summary**: This paper introduces EquiRNA, a hierarchical E(3)-equivariant GNN for RNA structure evaluation that decomposes RNA into atom-level, subunit-level, and nucleotide-level graphs, reusing nucleotide representations to handle size shifts. It also contributes rRNAsolo, a new benchmark dataset with a deliberate train/test size split (50–100 nt → 100–200 nt), and a size-insensitive KNN sampling strategy. Empirical results show EquiRNA outperforming existing methods across multiple metrics on both rRNAsolo and ARES.

**Strengths**:
1. Hierarchical architecture well-motivated by RNA biology - nucleotide reuse makes intuitive sense for size generalization.
2. New rRNAsolo dataset is a genuine contribution - ~7× larger than ARES, covers wider size range, includes more recent structures.
3. Comprehensive ablation validates each architectural component.
4. Strong empirical results across two datasets and multiple metrics.

**Weaknesses**:

**Major**: 
- Unclear/ambiguous numerical claim in text ("gains by 2.00 and 1.55 across Mean RMSD and Medium RMSD") - doesn't clearly match metrics in Table 1. Needs clarification.
- Size generalization claim not fully isolated from overall model quality - lacks control experiments.

**Minor**: 
- No runtime measurements despite efficiency claims.
- No statistical significance reported.

Let me also handle the "unequal tuning" criticism.

Actually, looking at the instructions more carefully:

"WEAKEN criticisms that are generic or one-size-fits-all and do not harm the core claim."

The unequal tuning criticism is a bit generic. Many papers use default baselines. Without evidence EquiRNA was tuned more, this is speculative. I'll weaken it.

Let me finalize my review now.Now I have all the information needed. Let me construct the final consolidated review.

---

## Summary

EquiRNA proposes a hierarchical E(3)-equivariant GNN for RNA structure evaluation that addresses size generalization by reusing nucleotide-level representations computed via atom-level and subunit-level message passing. The paper also contributes rRNAsolo, a new benchmark with an explicit size shift (training on 50–100 nt RNAs, testing on 100–200 nt), and a size-insensitive KNN sampling strategy. Empirical results across two datasets show consistent improvements over existing methods.

## Strengths

1. **Well-motivated hierarchical architecture for size generalization.** The three-level design (atom, subunit, nucleotide) is grounded in RNA biology — nucleotides are common building blocks shared across RNAs of varying sizes. The ablation study (Table 4) confirms each level contributes meaningfully, with removal of the nucleotide-level component causing a "significant decline in performance."

2. **New benchmark rRNAsolo is a genuine community asset.** The dataset is ~7× larger than ARES, spans a wider size range (training 50–100 nt, test 100–200 nt), includes more recent RNA structures, and uses TM-score clustering to prevent family-level data leakage. The deliberate train/test size split directly targets the size-generalization problem, and the paper's cleaning procedure is thorough and clearly described.

3. **Size-insensitive KNN sampling strategy is a thoughtful addition.** Fixing the neighbor size K at the nucleotide level regardless of total RNA length is a simple but principled way to ensure consistent local neighborhoods during training, directly mitigating size-imbalance issues. The ablation confirms its removal degrades performance.

4. **Comprehensive ablation studies validate design choices.** Table 4 systematically ablates each module (atom/subunit/nucleotide levels, KNN sampling, equivariance, atom/nucleotide templates), providing evidence that each component contributes.

5. **Consistent improvements across metrics and datasets.** EquiRNA outperforms all baselines on every metric on both rRNAsolo and ARES, including on the Relative Ranking metric (Table 3) which controls for high-RMSD artifacts in large RNAs.

## Weaknesses

### Fatal
None.

### Major

1. **Unclear/ambiguous numerical claim in the main results text.** The paper states: "Our model achieves the greatest performance gains by 2.00 and 1.55 across the Mean RMSD and Medium RMSD metrics on both validation and test sets." These numbers do not clearly correspond to any quantity in Table 1's reported columns (ER, DR, R-ER, R-DR). The text does not specify whether "2.00" and "1.55" refer to absolute RMSD values, differences from the best baseline, or relative error values. If these are intended as absolute RMSD improvements, they would be implausibly large (a ~40–50% reduction in RMSD) given the paper's overall tone and the modest margins the baselines show. This ambiguity undermines confidence in the quantitative claims and must be clarified. (*Section 4.1, paragraph 1.*)

2. **The evidence that the method *specifically* addresses size generalization is incomplete.** The central thesis is that EquiRNA's hierarchical design and KNN strategy specifically mitigate the challenge of generalizing from small (50–100 nt) to large (100–200 nt) RNAs. However, all baselines are also trained on the same small-to-large split — better performance on the test set could simply reflect a more expressive or better-optimized model overall, not a specific size-generalization advantage. The paper does not include a control experiment (e.g., training on the full size range and testing on large RNAs, or comparing the *generalization gap* — performance drop from small to large — across methods). Figure 5 shows EquiRNA is better at every size interval, but this is what one would expect from a stronger model; it does not isolate the size-generalization mechanism. The claim is not false, but it is stronger than the evidence directly supports. (*Section 4.1, Figure 5; Section 3.3 framing.*)

### Minor

3. **No quantitative support for efficiency claims.** The paper states EquiRNA "costs much less inference time than ARES" and is "even faster than EGNN" (Complexity Analyses, Section 4.1) but provides no runtime measurements, FLOP counts, parameter counts, or any quantitative comparison. Since efficiency is cited as a motivation in the abstract and introduction, the absence of supporting numbers is a noticeable gap.

4. **No statistical significance or variance reported.** None of the results include standard deviations or confidence intervals. Given that performance margins among methods are modest (the paper itself notes "small performance differences among SOTA models"), reporting single-run results makes it difficult to assess whether the improvements are reliable. This is standard practice in many benchmark papers, so it is a minor concern, but adding it would substantially strengthen the paper.

5. **Unequal tuning of baselines is a possible confound.** The paper states baselines were run with "default configurations in the corresponding source codes" (Section 4) but does not clarify whether EquiRNA's hyperparameters were similarly kept at defaults or were tuned. If EquiRNA was tuned while baselines were not, the comparison may be unfair. This is speculative without evidence of unequal treatment, but it is a reasonable question the authors should address.

### Trivial

6. The paper uses "Medium RMSD" in Section 4.1 text but "Median RMSD" in the metrics definition (Section 4) — inconsistent terminology.
7. The dataset construction section does not report basic summary statistics (e.g., number of TM-score clusters, RNA type breakdown) that would help readers assess diversity.

## Nice-to-Haves

- A control experiment training all methods on the full size range (50–200 nt) and evaluating on large RNAs (100–200 nt). If EquiRNA's advantage diminishes or disappears, that would directly confirm the benefit is tied to size-generalization mechanisms rather than overall model quality.
- Runtime wall-clock measurements on a fixed test set to substantiate the efficiency claims.
- A visualization or analysis showing that learned nucleotide embeddings are indeed similar for the same nucleotide type regardless of host RNA size, directly bridging the "reusing nucleotide representations" intuition and the empirical outcome.
- A limitations paragraph acknowledging that the approach was only tested up to 200 nt and may face challenges on much larger RNAs (>500 nt).

## Removed Points

These points are flagged to be removed; treat them with caution.

1. **Criticism about missing update equations for equivariant layers.** The harsh critic notes the paper lacks detailed update equations, but acknowledges this may be a parser-issue artifact (stripped appendix). Per instructions, weaknesses about missing appendix content are removed. The main text provides architectural description with Figure 3, which is sufficient for a conference paper at the concept level.

2. **Criticism that the ablation doesn't address the size-generalization hypothesis.** The harsh critic says the ablation "does not address the size-generalization hypothesis (which would require ablating the hierarchy and testing generalization gap)." This is essentially a restatement of Weakness #2 above and is not a separate weakness. It is subsumed by the broader concern about isolating the size-generalization mechanism.

3. **Strength Finder's claim about "Mean RMSD reduction of 2.00 over the best baseline."** This directly repeats the problematic numerical claim identified in Weakness #1. Since the weakness has identified this claim as unclear/ambiguous, the strength cannot be stated with confidence in this form. The strength about strong empirical results is retained in Strengths #5 without the disputed number.

4. **Harsh critic's claim that the paper is "overstated relative to what the evidence shows" and recommendation of "major revision."** These are opinion/summary statements that are absorbed into the overall assessment below rather than treated as distinct weaknesses.

5. **Criticism about missing dataset statistics (number of clusters, RNA type distribution).** This is partially valid — the paper does not report number of clusters — but the paper does report size ranges, number of RNAs and candidate structures, resolution filtering criteria, and chain count. The missing statistics are a minor presentational issue, now noted in Trivial #7 rather than treated as a major gap.

## Novel Insights

None beyond the paper's own contributions. The reviews surface a genuine tension: the paper's core architectural insight (hierarchical reuse of nucleotide representations for size generalization) is well-motivated and supported by ablations, but the experimental design does not fully decouple "better model" from "specifically better at size generalization." This is a constructive observation that the authors can address with targeted controls.

## Suggestions

1. **Clarify the numerical claim in Section 4.1.** State explicitly whether "2.00" and "1.55" refer to improvements in RMSD, relative error values, or some other quantity, and specify which table cells they correspond to. If these numbers are incorrect, correct them and recompute all downstream statements.

2. **Add a control experiment** training all methods on the full size range (50–200 nt) and testing on large RNAs (100–200 nt). If EquiRNA's advantage shrinks or disappears, this would directly confirm that its strength lies in size-specific mechanisms.

3. **Report runtime measurements** (e.g., wall-clock time per candidate structure on a fixed test set) to substantiate the efficiency claims.

4. **Add statistical significance** by running each method with multiple random seeds and reporting standard deviations, at least for the main results (Table 1).

## Score and Decision

This paper has genuine contributions — a well-motivated hierarchical architecture, a new and useful benchmark, and consistent empirical improvements. However, the central claim of "addressing size generalization" is not fully isolated from overall model quality, and the ambiguous numerical claim in the main results text undermines confidence in the quantitative reporting. These issues are fixable but as presented, the paper oversells what the evidence directly demonstrates.

**Score**: 6.0

**Decision**: Accept (borderline/weak accept, contingent on the authors addressing the numerical clarity issue and qualifying the size-generalization claim appropriately)

MY FINAL SCORE: <pineapple>6.0</pineapple>
MY FINAL DECISION: <orange>Accept</orange>